Literature DB >> 17061295

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.

Yuji Mano1, Takashi Usui, Hidetaka Kamimura.   

Abstract

The bile salt export pump (BSEP/Bsep/ABCB11) and multidrug resistance-associated protein 2 (MRP2/Mrp2/ABCC2) are involved in bile acid-dependent and -independent bile secretion, respectively. It has been reported that bosentan, an endothelin receptor antagonist, inhibits Bsep, which may lead to cholestatic liver injury due to the intracellular accumulation of bile salts, while increasing bile salt-independent bile flow. Thus, in this study, the effects of bosentan on BSEP/Bsep and MRP2/Mrp2 were evaluated using membrane vesicles derived from Spodoptera frugiperda (Sf) 9 cells, which express these transporters. The adenosine 5'-triphosphate (ATP)-dependent uptake of (3)H-taurocholic acid into membrane vesicles for BSEP/Bsep was inhibited by bosentan, and its IC(50) values were 76.8 and 101 microM for BSEP and Bsep, respectively. In contrast, bosentan stimulated the MRP2/Mrp2-mediated ATP-dependent vesicular transport of (3)H-estradiol 17beta-glucuronide by shifting the sigmoidal dependence of transport rate on substrate concentration to a more hyperbolic one. Collectively, these results suggest that bosentan inhibits BSEP in humans with a similar potency to rats, and that increased bile salt-independent flow in rats by bosentan is at least partly attributable to the activation of Mrp2. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17061295     DOI: 10.1002/bdd.527

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  14 in total

Review 1.  The determination and interpretation of the therapeutic index in drug development.

Authors:  Patrick Y Muller; Mark N Milton
Journal:  Nat Rev Drug Discov       Date:  2012-08-31       Impact factor: 84.694

2.  Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; K Münch; J Segrestaa; T Pfeifer; A Treiber; Mf Fromm
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 3.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors:  Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2013-05-07       Impact factor: 3.534

4.  Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.

Authors:  Kyunghee Yang; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-05-05       Impact factor: 3.922

5.  Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity.

Authors:  Dan Xu; Manhong Wu; Sachiko Nishimura; Toshihiko Nishimura; Sara A Michie; Ming Zheng; Zicheng Yang; Alexander John Yates; Jeffrey S Day; Kathleen M Hillgren; Saori Takedai Takeda; Yuan Guan; Yingying Guo; Gary Peltz
Journal:  J Pharmacol Exp Ther       Date:  2014-11-25       Impact factor: 4.030

6.  Association of CYP2C9*2 with bosentan-induced liver injury.

Authors:  S M Markova; T De Marco; N Bendjilali; E A Kobashigawa; J Mefford; J Sodhi; H Le; C Zhang; J Halladay; A E Rettie; C Khojasteh; D McGlothlin; A H B Wu; W-C Hsueh; J S Witte; J B Schwartz; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

Review 7.  Biochemical mechanisms in drug-induced liver injury: certainties and doubts.

Authors:  Ignazio Grattagliano; Leonilde Bonfrate; Catia V Diogo; Helen H Wang; David Q H Wang; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

8.  Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Authors:  Kari E Roberts; Ioana R Preston
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

9.  Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures.

Authors:  Robim M Rodrigues; Laxmikanth Kollipara; Umesh Chaudhari; Agapios Sachinidis; René P Zahedi; Albert Sickmann; Annette Kopp-Schneider; Xiaoqi Jiang; Hector Keun; Jan Hengstler; Marlies Oorts; Pieter Annaert; Eef Hoeben; Eva Gijbels; Joery De Kock; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Arch Toxicol       Date:  2018-05-14       Impact factor: 5.153

Review 10.  Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

Authors:  Christian F Opitz; Ralf Ewert; Wilhelm Kirch; David Pittrow
Journal:  Eur Heart J       Date:  2008-06-17       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.